Fig 2: EDD coimmunoprecipitates with BUB3 and BUBR1. A, MS/MS-based identification of HS-EDD copurifying proteins from HEK293 cells (n = 3). Any HS-EDD copurifying proteins identified in the HS-only sample were removed for the HS-EDD potential interactor list. The five top hits are shown and include the EDD bait, two mitochondrial proteins (MRS2 and C1QBP), BUB3, and Xaa-Pro aminopeptidase 3. B and C, HEK293 (B) and HeLa cells (C) were either transfected with the indicated constructs (B) or treated with either Noc or Tax (C) prior to IP with the indicated antibodies or IgG controls (Ctrl). Lysates (Input) and coimmunoprecipitates were analyzed by SDS-PAGE and Western blotting with the indicated antibodies. Quantification of immunoprecipitated EDD in C indicated a 69% and 81% reduction upon nocodazole and Taxol treatment, respectively. Images are representative of two independent experiments. Molecular weight standards are indicated. Note that EDD is 309 kDa and runs well above the high molecular weight marker (250 kDa).

Fig 3: EDD siRNA reduces mitotic frequency and success rate, but not mitotic timing. A–C, asynchronous HeLa cells were treated with EDD, BUBR1, or scrambled control (Con) siRNAs for 12 h prior to time-lapse microscopy. Cells were scored for their ability to initiate (A) and successfully complete mitosis (B), and we measured the duration of those successful mitoses (C). D, SDS-PAGE and Western blotting with the indicated antibodies validated the efficacy of siRNA-mediated knockdown. E–H, the fate of cells attempting mitosis was also assessed for overall cell death (E), death during mitosis (F), death following mitosis (G), and abnormal cytokinesis (e.g. fusion of daughter cells) (H). The total number of cells analyzed was >100 and, for mitotic cells, >40 for all siRNA-treated cell groups. The data in A, B, and E–H were analyzed by Fisher's exact test with the p value indicated, whereas the data in C were analyzed using one-way analysis of variance and Tukey's multiple comparison test, which revealed a significant difference between BUBR1 siRNA and the other three siRNA treatments. E–H incorporate pooled data from siEDD-1 and siEDD-2. Errors bars represent mean ± S.D.

Fig 4: EDD siRNA does not mediate G1 arrest but does increase p21 and γH2AX levels. A and B, HeLa cells were treated with scramble control (Con), EDD, BUBR1, or combined (Combo) siRNAs for 48 h and then analyzed by γH2AX (A) or propidium iodide FACS analysis (B). A, values represent the -fold increase over basal γH2AX levels (47) detected in scramble control cells. A, data were analyzed using unpaired Student's t test with the p value indicated. B, data were analyzed using one-way analysis of variance and Tukey's multiple comparison test, which revealed significant differences between the control and both BUBR1- and Combo siRNA-treated samples. A and B, errors bars represent mean ± S.E. from three experiments. C, SDS-PAGE and Western blotting with the indicated antibodies confirmed the EDD siRNA-mediated knockdown and induction of p21.

Fig 5: EDD coimmunoprecipitates with SAC- and APC-associated components. A and B, HeLa (A) and HCT116 (B) cells were treated with either EDD or scramble control siRNAs. Following siRNA treatment, lysates were immunoprecipitated with CDC20, BUBR1, or IgG control (Ctrl) antibodies, and coimmunoprecipitating proteins were analyzed by SDS-PAGE and Western blotting with the indicated antibodies. Ponceau Red-stained membranes are included as a loading control for the lysate inputs. Images are representative of two independent experiments.